thumbnail image


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文
  • LVGN7409

    Anti-CD40 agonistic monoclonal antibody

  • Clinical trials

    Phase I

    An Open Label, First in Human (FIH), Phase 1a/1b Trial of LVGN7409 (CD40 Agonist Antibody) as a Single Agent, in Combination With LVGN3616 (Anti-PD-1 Antibody), and in Combination With LVGN3616 and LVGN6051 (CD137 Agonist Antibody) in Patients With Locally Advanced, Relapsed, Refractory, or Metastatic Malignancy
    NCT04635995
    VIEW TRIAL
     
    An Open Label, Phase I Trial of LVGN7409 as Single Agent in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
    NCT05152212
    VIEW TRIAL
     
    Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
    NCT05075993
    VIEW TRIAL

     

    CD40, agonist, agonistic antibody, fcgriib, fc, immune therapy, tnfrsf, LVGN7409, lyvgen

    More about LVGN7409

    CD40 is a costimulatory protein found on antigen-presenting cells (APCs) and is required for their activation. The binding of CD154 (CD40L) on T cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.
    Similar to the endogenous CD40 ligand (CD40L or CD154), CD40 agonistic antibody LVGN7409 binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Evidence to date suggests that CD40 activation is a critical and nonredundant mechanism to convert so-called cold tumors to hot ones (with prominent tumor infiltration of T cells), sensitizing them to checkpoint inhibition.
    Based on different expression profile and anti-tumor activity mechanism between CD40 and other T-cell activating drugs, anti-CD40 antibody is an excellent candidate for combination therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 antibodies etc.
    For more scientific rationale, please visit Cancer Immunotherapy and xLink MAb.


    Our Progress

    We are conducting Phase I trials of LVGN7409 as monotherapy and in combination with PD-1 antibodies in the USA and China, in adult patients with advanced malignancies.
    If you as a patient or caregiver wish to participate in this study, please contact us at the following address: clinical@lyvgen.com or send us a message
    Contact us

    Lyvgen website is designed to provide general information about the subject matter presented. The information presented does not, and is not intended to, provide medical advice.

沪公网安备 31011502015346号
|
沪ICP备20018873号-2
    Home
    About us
    xLinkAb
    Contact us
Lyvgen Biopharma Website 礼进生物 英文官网
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
Cookie的使用
我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
了解更多